GIKLY
Price
$7.04
Change
-$0.01 (-0.14%)
Updated
Jul 18 closing price
Capitalization
8.78B
One day until earnings call
NVSEF
Price
$115.50
Change
+$0.25 (+0.22%)
Updated
Jul 25 closing price
Capitalization
216.52B
Interact to see
Advertisement

GIKLY vs NVSEF

Header iconGIKLY vs NVSEF Comparison
Open Charts GIKLY vs NVSEFBanner chart's image
Grifols Sa
Price$7.04
Change-$0.01 (-0.14%)
Volume$103
Capitalization8.78B
Novartis AG
Price$115.50
Change+$0.25 (+0.22%)
Volume$110
Capitalization216.52B
GIKLY vs NVSEF Comparison Chart in %
Loading...
GIKLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVSEF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GIKLY vs. NVSEF commentary
Jul 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GIKLY is a Hold and NVSEF is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 28, 2025
Stock price -- (GIKLY: $7.04 vs. NVSEF: $115.50)
Brand notoriety: GIKLY and NVSEF are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GIKLY: 9% vs. NVSEF: 1%
Market capitalization -- GIKLY: $8.78B vs. NVSEF: $216.52B
GIKLY [@Pharmaceuticals: Major] is valued at $8.78B. NVSEF’s [@Pharmaceuticals: Major] market capitalization is $216.52B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GIKLY’s FA Score shows that 1 FA rating(s) are green whileNVSEF’s FA Score has 2 green FA rating(s).

  • GIKLY’s FA Score: 1 green, 4 red.
  • NVSEF’s FA Score: 2 green, 3 red.
According to our system of comparison, NVSEF is a better buy in the long-term than GIKLY.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GIKLY’s TA Score shows that 2 TA indicator(s) are bullish while NVSEF’s TA Score has 5 bullish TA indicator(s).

  • GIKLY’s TA Score: 2 bullish, 3 bearish.
  • NVSEF’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, NVSEF is a better buy in the short-term than GIKLY.

Price Growth

GIKLY (@Pharmaceuticals: Major) experienced а 0.00% price change this week, while NVSEF (@Pharmaceuticals: Major) price change was -2.70% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +3.43%. For the same industry, the average monthly price growth was +7.37%, and the average quarterly price growth was +13.00%.

Reported Earning Dates

GIKLY is expected to report earnings on Jul 29, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+3.43% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NVSEF($217B) has a higher market cap than GIKLY($8.79B). GIKLY has higher P/E ratio than NVSEF: GIKLY (75.19) vs NVSEF (29.50). GIKLY YTD gains are higher at: 49.787 vs. NVSEF (20.187). NVSEF has higher annual earnings (EBITDA): 17.8B vs. GIKLY (726M). NVSEF has more cash in the bank: 11.2B vs. GIKLY (557M). GIKLY has less debt than NVSEF: GIKLY (10.9B) vs NVSEF (28.3B). NVSEF has higher revenues than GIKLY: NVSEF (53.1B) vs GIKLY (6.46B).
GIKLYNVSEFGIKLY / NVSEF
Capitalization8.79B217B4%
EBITDA726M17.8B4%
Gain YTD49.78720.187247%
P/E Ratio75.1929.50255%
Revenue6.46B53.1B12%
Total Cash557M11.2B5%
Total Debt10.9B28.3B39%
FUNDAMENTALS RATINGS
GIKLY vs NVSEF: Fundamental Ratings
GIKLY
NVSEF
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
21
Undervalued
15
Undervalued
PROFIT vs RISK RATING
1..100
10036
SMR RATING
1..100
8729
PRICE GROWTH RATING
1..100
3853
P/E GROWTH RATING
1..100
9383
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NVSEF's Valuation (15) in the null industry is in the same range as GIKLY (21). This means that NVSEF’s stock grew similarly to GIKLY’s over the last 12 months.

NVSEF's Profit vs Risk Rating (36) in the null industry is somewhat better than the same rating for GIKLY (100). This means that NVSEF’s stock grew somewhat faster than GIKLY’s over the last 12 months.

NVSEF's SMR Rating (29) in the null industry is somewhat better than the same rating for GIKLY (87). This means that NVSEF’s stock grew somewhat faster than GIKLY’s over the last 12 months.

GIKLY's Price Growth Rating (38) in the null industry is in the same range as NVSEF (53). This means that GIKLY’s stock grew similarly to NVSEF’s over the last 12 months.

NVSEF's P/E Growth Rating (83) in the null industry is in the same range as GIKLY (93). This means that NVSEF’s stock grew similarly to GIKLY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GIKLYNVSEF
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
53%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
69%
Bullish Trend 3 days ago
63%
Momentum
ODDS (%)
N/A
Bearish Trend 3 days ago
47%
MACD
ODDS (%)
Bearish Trend 3 days ago
56%
Bearish Trend 3 days ago
36%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
56%
Bearish Trend 3 days ago
48%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
57%
Bullish Trend 3 days ago
49%
Advances
ODDS (%)
N/A
Bullish Trend 3 days ago
53%
Declines
ODDS (%)
N/A
Bearish Trend 13 days ago
42%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
72%
Bullish Trend 3 days ago
50%
Aroon
ODDS (%)
Bullish Trend 3 days ago
62%
Bullish Trend 3 days ago
46%
View a ticker or compare two or three
Interact to see
Advertisement
GIKLY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NVSEF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
ACP5.950.07
+1.19%
abrdn Income Credit Strategies Fund
COWZ57.250.21
+0.37%
Pacer US Cash Cows 100 ETF
CPSD25.080.05
+0.21%
Calamos S&P 500 Str Alt Prt ETF-Dec
APRT39.880.08
+0.20%
AllianzIM US Large Cap Buffer10 Apr ETF
BKCH61.64-1.37
-2.18%
Global X Blockchain ETF

GIKLY and

Correlation & Price change

A.I.dvisor tells us that GIKLY and OPHLY have been poorly correlated (+10% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that GIKLY and OPHLY's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GIKLY
1D Price
Change %
GIKLY100%
N/A
OPHLY - GIKLY
10%
Poorly correlated
-0.82%
GLAXF - GIKLY
8%
Poorly correlated
+0.90%
NVSEF - GIKLY
7%
Poorly correlated
+0.22%
ORINY - GIKLY
4%
Poorly correlated
N/A
KYKOF - GIKLY
3%
Poorly correlated
N/A
More

NVSEF and

Correlation & Price change

A.I.dvisor tells us that NVSEF and SNYNF have been poorly correlated (+26% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NVSEF and SNYNF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVSEF
1D Price
Change %
NVSEF100%
+0.22%
SNYNF - NVSEF
26%
Poorly correlated
+4.11%
GIKLY - NVSEF
7%
Poorly correlated
N/A
KYKOF - NVSEF
5%
Poorly correlated
N/A
OPHLY - NVSEF
2%
Poorly correlated
-0.82%
GLAXF - NVSEF
1%
Poorly correlated
+0.90%
More